Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

2.35EUR
15 Dec 2017
Change (% chg)

€-0.08 (-3.10%)
Prev Close
€2.42
Open
€2.42
Day's High
€2.46
Day's Low
€2.22
Volume
2,051,235
Avg. Vol
796,166
52-wk High
€4.26
52-wk Low
€2.04

Chart for

About

Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical... (more)

Overall

Beta: 1.53
Market Cap(Mil.): €690.21
Shares Outstanding(Mil.): 222.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

* THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA

15 Dec 2017

BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma

* SAYS PRESENTS POSITIVE RESULTS OF ADMYRE PHASE III TRIAL OF PLITIDEPSIN IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Dec 2017

BRIEF-Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue

* PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE) Source text for Eikon:

15 Nov 2017

BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma

* PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA

13 Nov 2017

BRIEF-Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment

* SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY

09 Nov 2017

BRIEF-Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

* SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA

07 Nov 2017

BRIEF-Pharma Mar 9-month net loss narrows to 14.5 mln euros YoY

* 9-MONTH REVENUE 140.4 MILLION EUROS VERSUS 139.6 MILLION EUROS YEAR AGO

24 Oct 2017

BRIEF-Pharma Mar presents updated data from Zepsyre Phase I/II trials in SCLC‍​

* PROGRESSION FREE SURVIVAL BENEFIT OBSERVED IN COMBINATION OF PM1183 AND DOXORUBICIN IN SMALL-CELL LUNG CANCER (SCLC)

18 Oct 2017

BRIEF-Pharma Mar submits MAA for Aplidin in Switzerland for multiple myeloma treatment

* SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) FOR APLIDIN IN SWITZERLAND FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA‍​ Source text: http://bit.ly/2xf24h3

04 Oct 2017

BRIEF-Pharma Mar starts clinical studies with new compound PM14 in patients with solid tumors

* SAYS STARTS CLINICAL STUDIES WITH NEW COMPOUND PM14 IN PATIENTS WITH SOLID TUMORS Source text for Eikon:

19 Sep 2017

Earnings vs. Estimates